Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The study compares the adherence of 240 HIV-negative subjects randomly assigned to 2
different antiretroviral therapies for 28 days after accidental exposure to HIV.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Clinic of Barcelona
Treatments:
Atazanavir Sulfate Lamivudine Lamivudine, zidovudine drug combination Lopinavir Zidovudine